Aarti Pharmalabs Limited — PPTs, 13-08-2025: Investor Presentation

Here's a summary of the attached document, adhering to your preferences:

**1. Financial Highlights:**

Q1-FY26 consolidated revenue: ₹386.2 Cr. EBITDA: ₹95.3 Cr (24.68% margin). PAT: ₹49.5 Cr (12.82% margin). *Note: Current quarter figures not directly comparable due to a joint venture accounting change.* FY25 revenue: ₹2,115.1 Cr; Net Debt/Equity: 0.19x.

**2. Strategic Initiatives & Growth Drivers:**

Key capex includes a ₹400 Cr Atali greenfield project for CDMO/Intermediates (Q2-FY26 mechanical completion), scalable 8-10x. A ₹150 Cr Tarapur expansion boosts Xanthine capacity to 9,000 MTPA by Q4-FY26, targeting 20-25% global share. FY26 outlook projects 30-40% CDMO revenue growth and 12-15% EBITDA growth.

**3. Business Developments:**

Recent strides include activating a third R&D center, securing USFDA approval for Dombivli, enhanced Xanthine capacity, expanded Vapi production, and initiated a 21 MW solar power project.

**4. Market Position & Competitive Advantage:**

APL is India's largest Xanthine Derivatives manufacturer (15-20% global share) with backward integration. A specialized HPAPI player and leading small molecule CDMO/CMO provider, leveraging multiple USFDA-approved facilities.

**5. Investor Implications:**

Substantial capex at Atali and Tarapur suggests strong future growth potential in high-margin CDMO/CMO and Xanthine. Despite Q1 declines (due to JV accounting), strategic initiatives indicate a focus on long-term expansion and market leadership.